Indian Drugmakers Seek to Sway Trump Over Cheap Generic Imports
- Early signs from Trump administration don’t ‘augur well’
- Exemption for generic drugs in proposed border tax is one goal
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
India’s largest pharmaceutical firms are looking to convince U.S. President Donald Trump that his promise to lower drug costs should take priority over his vow to make sure the medicines are made in America.
Savings from cheaper imported drugs will outweigh the jobs created by producing them in the U.S., the Indian Pharmaceutical Alliance, which represents drugmakers including Sun Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd., said in a report obtained by Bloomberg News. One goal could be to win an exemption for generic drugs under any border-tax policy that is enacted in the U.S., it said.